NCT05848284招募中不适用
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- VDyne, Inc.
- 入组人数
- 30
- 试验地点
- 22
- 主要终点
- Changes in symptom status (NYHA class)
研究概览
简要总结
The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Symptomatic severe tricuspid valve regurgitation of primary or secondary etiology.
- •NYHA class ≥ II. If NYHA Class IV, patient must be ambulatory.
- •Subject is adequately treated with medical therapy for heart failure ≥ 30 days prior to
- •index procedure, including a diuretic.
- •Heart Team determines patient is a recommended candidate for the VDyne System.
- •Age >18 years at time of index procedure.
- •Clinical Screening Committee (CSC) and Imaging Core Labs confirm suitability for treatment with the VDyne System.
排除标准
- •Patient anatomy (cardiac and vascular) is not suitable for VDyne System as assessed by Imaging Core Labs, Sponsor or Clinical Screening Committee (CSC)
- •Intolerance to procedural anticoagulation or post-procedural antiplatelet/ anticoagulation regimen that cannot be medically managed
- •Hypersensitivity to nickel or titanium
- •Left Ventricular Ejection Fraction (LVEF) <30%.
- •Severe RV dysfunction.
- •Significant abnormalities of the tricuspid valve and sub-valvular apparatus.
- •Sepsis including active infective endocarditis (IE) (within last 6 months).
- •Right ventricular, atrial thrombus, vegetation or mass on tricuspid valve.
- •Severe tricuspid annular or leaflets calcification.
- •Systolic pulmonary hypertension with systolic pulmonary artery pressure >70 mmHg.
- •History or rheumatic fever
- •Significant coronary artery disease requiring treatment such as symptomatic, unresolved multi-vessel or unprotected left main coronary artery disease.
- •Any planned surgery or interventional procedure within 30 days prior to or 30 days following the implant procedure. This includes any planned concomitant cardiovascular procedure such as CABG, PCI, pulmonary vein ablation, left atrial appendage occlusion, septal defect repair, etc.
- •Unresolved severe symptomatic carotid stenosis (> 70% by ultrasound).
- •Cardiac resynchronization therapy device or implantable pulse generator implanted within 60 days of planned implant procedure.
- •Permanent pacing leads that will interfere with delivery or implantation of the VDyne Valve.
- •Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure.
- •Prior tricuspid valve surgery or catheter-based therapy with permanent residual device(s) implanted that would preclude delivery or implantation of the VDyne Valve (e.g. valve replacement, edge to edge repair, etc.).
- •Significant valvular heart disease requiring intervention other than the tricuspid valve.
- •Known significant intracardiac shunt (e.g. septal defect)
- •Cerebrovascular accident (stroke, TIA) within 6 months of treatment procedure.
- •Severe lung disease (severe COPD or continuous use of home oxygen or oral steroids).
- •Acute myocardial infarction (AMI) within 30 days.
- •Significant renal dysfunction (eGFR<30 ml/min/1.73m2) or on dialysis.
- •End-stage liver disease (MELD > 11 / CHILD class C).
- •Bleeding requiring transfusion within prior 30 days.
- •Coagulopathy or other clotting disorder that cannot be medically managed.
- •Chronic immunosuppression or other condition that could impair healing response.
- •Any of the following: leukopenia, chronic anemia (Hgb < 9), thrombocytopenia, history of bleeding diathesis, or coagulopathy.
- •Unwilling to receive blood products.
- •Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution) which cannot be adequately managed medically.
- •Life expectancy less than 12 months due to non-cardiac comorbidities.
- •Treatment is not expected to provide benefit (futile).
- •Current IV Drug user (must be free drug abuse for > 1 year).
- •Pregnant, lactating or planning pregnancy within next 12 months.
- •Vulnerable patient groups (minors, cognitively impaired persons, prisoners, persons whose willingness to volunteer could be unduly influenced by the expectation of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate, such as students, residents, and employees).
- •Currently participating in an investigational drug or device trial that has not reached its primary endpoint or is likely to interfere with this study.
- •Patient (or legal guardian) unable or unwilling to provide written, informed consent before study enrollment.
- •Patient unable or unwilling to comply with study required testing and follow-up visits
研究组 & 干预措施
VDyne System Treatment Arm
Experimental
Device
干预措施: VDyne Transcatheter Tricuspid Valve Replacement System (Device)
结局指标
主要结局
Changes in symptom status (NYHA class)
时间窗: Baseline to 1 month after implant
Changes in symptom status (NYHA class)
Changes in in quality of life (KCCQ score)
时间窗: Baseline to 1 month after implant
Changes in in quality of life (KCCQ score). A higher score indicates worsening quality of life outcomes
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC).
时间窗: Implant to 30 days post-procedure
The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC).
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs
时间窗: Baseline to 1 month after implant
Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs
Changes in functional capacity (6-minute walk test)
时间窗: Baseline to 1 month after implant
Changes in functional capacity (6-minute walk test)
次要结局
- Changes in right ventricle as measured by core lab(1 month after implant to 1 year post-implant)
- Changes in symptom status (NYHA class)(1 month after implant to 1 year post-implant)
- Changes in in quality of life (KCCQ score).(1 month after implant to 1 year post-implant)
- The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) after 30 days to 1 year of the procedure, as classified by the Clinical Events Committee (CEC).(30 days post-procedure to 1 year)
- Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs(1 month after implant to 1 year post-implant)
- Rate of heart failure hospitalization(1 month after implant to 1 year post-implant)
- Changes in functional capacity (6-minute walk test)(1 month after implant to 1 year post-implant)
研究者
研究点 (22)
Loading locations...
相似试验
招募中
不适用
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid RegurgitationTricuspid Valve DiseaseTricuspid Valvular DisordersTricuspid RegurgitationNCT05797519VDyne, Inc.120
已完成
不适用
BIOFLOW-INDIA Safety and Clinical PerFormance of the Drug Eluting ORSIRO Stent in Single de Novo Coronary Artery LesionsCoronary Artery DiseaseNCT01426139Biotronik AG120
终止
不适用
DESyne in Routine Clinical PracticeAngioplasty, Transluminal, Percutaneous CoronaryCoronary Artery DiseaseNCT02039713Seung-Jung Park342
进行中（未招募）
不适用
PrizValve® Transcatheter Aortic Valve Replacement StudyAortic Valve StenosisNCT04836897Shanghai NewMed Medical Co., Ltd.120
招募中
不适用
Valveclip® Transcatheter Mitral Valve Repair StudyMitral RegurgitationNCT05021614Shanghai NewMed Medical Co., Ltd.150